CAPA Under the FDA QMSR: Corrective Action, Preventive Action, and Inspection Readiness

Overview:

Under the FDA’s new Quality Management System Regulation, CAPA is no longer something medical device companies can treat as a routine quality-system activity or a documentation exercise after a problem has already occurred. The shift to the QMSR places greater attention on how manufacturers identify quality signals, evaluate risk, investigate complaints and nonconformities, determine root cause, separate corrective action from preventive action, and show that actions taken are effective before closure.

For many medical device companies, this is where the pressure is building. Complaint files, post-market surveillance data, manufacturing nonconformities, MDR and recall considerations, customer feedback, risk analysis, and management review are often handled by different functions. Under the QMSR, those inputs need to connect more clearly. A weak CAPA system can lead to recurring problems, delayed escalation, incomplete investigations, poor effectiveness checks, or corrective actions that either overwhelm the system or fail to address the real issue.

The challenge is not simply opening more CAPAs. In fact, too many corrective actions can slow the quality system, while too few can allow serious trends to go unaddressed. Device manufacturers need a balanced, risk-based approach that helps them decide when an issue is a complaint, when it requires investigation, when it should become a corrective action, when preventive action is needed, and how those decisions should be documented and reviewed.

This webinar will examine the updated expectations for corrective action and preventive action under the QMSR and explain how post-market surveillance, complaint handling, risk analysis, root cause determination, MDR and recall decision-making, investigation reports, action plans, verification/validation, post-closing effectiveness checks, metrics, and management review fit together. The session will also address why separate CA and PA processes, supported by strong SOPs and cross-functional information sharing, are important for maintaining a CAPA program that is both compliant and manageable.

By the end of the session, attendees will have a clearer understanding of how to build and maintain a practical post-market surveillance, complaint, corrective action, and preventive action system that aligns with the new FDA QMSR expectations while supporting device safety, quality, and ongoing compliance.

Areas Covered in the Session:

• Sources of information, including complaints and post-market surveillance
• Information gathering and proactive information gathering
• Information evaluation: complaint determination, CA determination, and investigation decisions
• Risk analysis applied to corrective action and preventive action
• Root cause determination
• CA and PA investigation report and action plan
• Verification and validation of CA and PA actions
• Post-closing effectiveness checks
• CA and PA program metrics and management review
• MDR and recall decision-making within the CA and PA process
• Post-market surveillance, including customer surveys
• Integration of manufacturing nonconformities with the CA and PA program
• New CA and PA expectations under the FDA QMSR
• Separate corrective action and preventive action processes and SOP considerations

To support implementation of the concepts discussed during the webinar, attendees will receive the following handouts:

• QMSR CAPA Decision Pathway Checklist
• Corrective Action vs. Preventive Action Scenario Workbook
• CAPA Effectiveness Check & Management Review Readiness Template

Why Should You Attend?

The FDA has long viewed CAPA as one of the most important indicators of the health of a medical device quality system. Under the new QMSR, expectations surrounding corrective action, preventive action, complaint handling, risk evaluation, post-market surveillance, and management involvement have become more closely connected. Organizations that continue to rely on legacy CAPA practices may find it difficult to demonstrate that issues are identified, investigated, escalated, and resolved in a manner that satisfies current regulatory expectations.

This webinar will help you understand how the various elements of a modern CAPA program fit together—from complaints and post-market surveillance data to risk analysis, root cause investigations, effectiveness verification, and management review. You will gain practical insight into determining when corrective action is warranted, when preventive action should be initiated, and how to maintain a system that remains effective without becoming unnecessarily burdensome.

Whether you are updating procedures to align with the QMSR, strengthening complaint handling processes, preparing for FDA inspections, or looking to improve the effectiveness of your quality system, this session will provide valuable guidance for building a CAPA program that supports compliance, product quality, and patient safety.

Who will benefit?

This webinar is designed for medical device professionals responsible for CAPA, complaint handling, post-market surveillance, risk management, and QMSR readiness. It will be especially useful for those who must document, review, approve, or defend CA and PA decisions, including:

• Quality Assurance Managers
• Quality Systems Managers
• CAPA Managers
• CAPA Specialists
• Complaint Handling Managers
• Post-Market Surveillance Managers
• Regulatory Affairs Managers
• Medical Device Compliance Managers
• Risk Management Professionals
• Manufacturing Quality Managers
• Quality Engineers
• Supplier Quality Engineers
• Design Quality Engineers
• Validation Managers
• Clinical Evaluation / PMS Specialists
• MDR Reporting Specialists
• Recall Coordinators
• Internal Auditors
• Management Review Coordinators
• Medical Device Consultants
• Medical Device Company Executives